Company News For Jan 4, 2019

Zacks Equity Research Published on January 04, 2019

Shares of Bristol-Myers Squibb Company (BMY - Free Report) declined 13.3% after it announced that it will acquire Celgene Corporation for $74 billion in cash and stock
Shares of Delta Air Lines, Inc. (DAL - Free Report) declined 8.9% after the company stated that it expected its December revenue to grow 3%, lower than the previous projection of 3.5%
Tribune Media Company’s shares slumped 0.1% after the company pulled its TV stations from Spectrum, the Charter Communications owned cable operator after the two parties could not reach a carriage agreement
Atara Biotherapeutics, Inc.’s (ATRA - Free Report) shares slumped 19.5% after the company’s CEO Isaac Ciechanover announced plans to step down

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.